Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1999-05-07
2000-06-06
Henley, III, Raymond
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
A61K 3800
Patent
active
060718803
ABSTRACT:
In accordance with the present invention, there are provided methods for the treatment of chronic renal insufficiencies and related chronic indications in mammals, employing IGF-I as the active agent. In accordance with one embodiment of the present invention, it has been discovered that IGF-I is an effective agent for enhancing kidney development in mammals suffering from chronic organ injury. In accordance with a further embodiment of the present invention, it has been discovered that IGF-I is an effective agent for protecting prepubescent subjects, such as prepubescent mammals and neonates, from the ongoing toxicity of treatment with steroid hormones. In accordance with a still further embodiment of the present invention, it has been discovered that IGF-I is an effective agent for maintaining substantially normal growth in neonates and pre-pubescent mammals exposed to high dose steroid hormone therapy.
REFERENCES:
patent: 3773919 (1973-11-01), Boswell et al.
patent: 4485045 (1984-11-01), Regen
patent: 5128320 (1992-07-01), Hahn et al.
patent: 5258287 (1993-11-01), Baxter et al.
patent: 5270313 (1993-12-01), Burri et al.
patent: 5273961 (1993-12-01), Clark
patent: 5292740 (1994-03-01), Burri et al.
patent: 5565428 (1996-10-01), Clark et al.
Avner et al., "A new model of glucocorticoid-induced metanephric maldevelopment" Experientia, 40:489-490 (1984).
Avner et al., "Triiodothyronine-induced cyst formation in metanephric organ culture: The role of increased Na-K-adenosine triphoshates activity" J. Lab. Clin. Med., 109:441-453 (1987).
Avner et al., "Sodium-potassium ATPase activity mediates cyst formation in metanephric organ culture" Kidney Int.,, 28:447-455 (1985).
Avner et al., "In vitro modulation of tubular cyst regression in murine polycystic kidney disease" Kidney Int., 36:960-968 (1989).
Baxter, T. J., "Cortisone-Induced Renal Changes in the Rabbit: A Microdissection Study" Brit. J. Exp. Path., 40:140-149 (1960).
Calvet, J.P., "Polycystic kidney disease: Primary extracellular matrix abnormality of defective cellular diffentiation?" Kidney Int., 43:101-108 (1993).
Charlton, H. M., "Mouse Mutants as Model in Endocrine Research" Quarterly J. Exp. Physiol., 69:655-676 (1984).
Churchill et al., "Prognosis of adult onset polycystic kidney disease re-evaluated " Kidney Intl., 26:190-193 (1984).
Cowley et al., "Elevated c-myc protooncogene expression in autosomal recessive polycystic kidney disease" Proc. Natl. Acad. Sci. USA, 84:8394-8398 (1987).
Crocker, J.F.S., "Chemically Induced Polycystic Kidney Disease" In Abnormal Functional Development of the Heart, Lungs and Kidneys, Eds. Kavlock and Grabowski, Liss, New York, p. 281-296 (1983).
Crocker et al., "Steriod-Induced Polycystic Kidneys in the Newborn Rat" Am. J. Path., 82:373-380 (1976).
Crocker and McDonald, "Effects of Lithium Chloride and Ethacrynic Acid on Experimental Polycystic Kidney Disease" Clin. Invest. Med., 11(1):16-21 (1988).
Crocker et al., "Polycystic kidney and liver disease and corticosterone changes in the cpk mouse" Kidney Int., 31:1088-1091 (1987).
Crocker and Ogborn, "Glucocorticoid Teratoogenesis in the Developing Nephron" Teratology, 43:571-574 (1991).
Danovitch, G. M., "Clinical Features and Pathophysiology of Polycystic Kiddney Disease in Man" Cystic Diseases of the Kidney, Gardner, K. D. (ed), John Wiley & Sons Inc., Toronto, p. 125-150 (1975).
Davisson et al., "The Mouse polycystic Kidney Disease Mutation (cpk) Is Located on Proximal Chromosome 12" Genomics, 9:778-781 (1991).
Ebihara et al., "Altered mRNA Expression of Basement Membrane Components in a Murine Model of Polycystic Kidney Disease" Lab. Invest., 58(3):262-269 (1988).
Filmer et al., "Adrenal Corticosteriod-Induced Renal Cystic Disease in the Newborn Hamster" Am. J. Path., 72(3):461-468 (1973).
Forsthoefel et al., "Glucocorticoid Regulation of Transcription of the c-myc cellular Protooncogene in P1798 Cells" Molec. Endocrin., 1(12): 899-907 (1987).
Genetic Variants and Strains of Laboratory Mouse, 2nd edition, Eds Lyon and Searle, Oxford University Press.
Germino et al., "Identification of Locus a Which Shows No Genetic Recombination with the Autosomal Dominant Polycystic Kidney Disease Gene on chromosome 16" Am. J. Hum. Genet., 46:925-933 (1990).
Grimm et al., J. Exp. Path., 71: 119-131 (1990).
Grunfeld et al., "Liver Changes and Complications in Adult Polycystic Kidney Disease" Advances in Nephrology, 14:1-20.
Handbook on Genetically Standardized Jax Mice, 3rd edition, Eds Heiniger and Dorey, The Jackson Laboratory.
Humes et al., "Interaction between Growth Factors and Retinoic Acid in the Induction of Kidney Tubulogenesis in Tissue Culture" Exp. Cell Res., 201:8-15 (1992).
Ihara et al., "Biological Profiles of Highly Potent Novel Endothelin Antagonists Selective for the ET.sub.A Receptor" Life Science, 50(4):247-250 (1992).
Ihara et al., "An Endothelin Receptor (ET.sub.A) Antagonist Isolated From Streptomyces misakiensis" Biochim. Biophys. Res. Comm., 178(1):132-137 (1991).
Kimberling et al., "Linkage Heterogeneity of Autosomal Dominant Polycystic Kidney Disease" NEJM, 319(14):913-918 (1988).
Langer et al., "Biocompatibility of polymeric delivery systems for maromolecules" J. Biomed. Mater. Res., 15:267-277 (1981).
Martin and Baxter, "Insulin-like Growth Factor-binding Protein from Human Plasma" J. Biol. Chem., 261: 8754-8760 (1986).
Mattei et al., "Chromosomal Assignment of Retinoic Acid Receptor (RAR) Genes in the Human, Mouse, and Rat Genomes" Genomics, 10:1061-1069 (1991).
McDonald et al., "Glucocorticooid-induced polycystic kidney disease-A threshold trait" Kidney Int., 37:901-908 (1990).
Nidess et al., "Development of the Embryonic Murine Kidney in Normal and Congenital Polycystic Kidney Disease: Characterization of a Proximal Tubular Degenerative Process as the First Obsercable Light Microscopic Defect" J. Urol., 131:156-162 (1984).
Ogborn et al., "Ontogeny of Renal Glucocorticoid Receptors Regulates Differing Prevalence of Polycystic Kidney Disease in Inbred Mice" Kidney Int., 37: 425 (1990).
Ogborn et al., "Renal Sodium Potassium Atpase (NAKATPASE) Induction In Vivo In Newborn Mice: A Potential Modulator of Experimental Polycystic Kidney Disease" Pediatr. Res., 27:335A (1990).
Ojeda et al., "Polycystic Kidney Disease Induced by Corticoids" Nephron., 42:240-248 (1986).
Parfrey et al., "The Diagnosis and Prognosis of Autosomal Dominanat Polycystic Kidney Disease" NEJM, 323:1085-1090. (1990).
Perey et al., "Polycystic Renal Disease: A new Experimental Model" Science, 158: 494-496 (1967).
Preminger et al., "Murine Congenital Polycystic Kidney Disease: A Model for Studying Development of Cystic Disease" J. Urol., 127: 556-560 (1982).
Ragsdale and Brockes, "Retinoids and their targets in vertebrate development" Current Opinion in Cell Biol., 3:928-934 (1991).
Reeders et al., "A highly polymorphic DNA marker linked to adult polycystic kidney disease on chromosome 16" Nature, 317:542-544 (1985).
Rinderknecht, et al., "Polypeptides with nonsuppressible insulin-like and cell-growth promoting activities in human serum:Isolation, chemical characterzation, and some biological properties of form I and II" Proc. Natl. Acad. Sci. USA, 73(7): 2365-2369 (1976).
Sidman et al., "Controlled Release of Macromolecules and Pharmaceuticals from Synthetic Polypeptides Based on Glutamic Acid" Biopolymers, 22:547-556 (1983).
Taitz et al., "Screening for polycystic kidney disease: importance of clinical presentation in the newborn" Arch. Dis. Child., 62: 45-49 (1987).
Trudel et al., "c-myc as an inducer of polycystic kidney disease in transgenic mice" Kidney Int., 39: 665-671 (1991).
Wade et al., "Modulation of Cell Membrane Area in Renal Collecting Tubules by Corticosteroid Hormones" J. Cell Biol. 81:439-445 (1979).
Webb et al., "The Endothelin Receptor Antagonist, BQ-123, Inhibits Angiotensin II-Induced Contractions in Rabbit Aorta" Biochem. Biophys. Res. Comm., 185: 887-892 (1992).
Wirth et al., "Autosomal recessive and dominant forms polycystic kidney disease are not allelic" Hum. Genet, 77:221-222 (1987).
Acott Philip D.
Crocker John F. S.
Dalhousie University
Henley III Raymond
Reiter Stephen E.
LandOfFree
Use of IGF-I for the treatment of renal insufficiencies, steriod does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of IGF-I for the treatment of renal insufficiencies, steriod, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of IGF-I for the treatment of renal insufficiencies, steriod will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2213582